Genome Web Breaking News

The Chinese sequencing company previously nabbed medical device registrations for the G99 sequencer in the EU, Australia, Singapore, Japan, Thailand, and the UK.

Last week, GenomeWeb's readers were most interested in Jacob Thaysen joining Illumina as new CEO from Agilent Technologies.

Under the agreement, Plus is using the cerebrospinal fluid cell-based assay in its ongoing clinical trial of the radiotherapeutic rhenium 186 obisbemeda.

New products and services posted to GenomeWeb for the week of Sept. 4, 2023

Executive appointments, promotions, and departures in omics and molecular diagnostics for the week of Sept. 4, 2023

Using matched tumor-normal genome sequencing, investigators discovered distinct mutational processes in three clusters of high-risk or non-high-risk neuroblastoma cases.

Investigators used genetic fine mapping and multiomics to identify 436 blood pressure-related candidate effector genes, some of which could become drug targets. 

The partners will offer their combined expertise to biopharma companies developing diagnostics and clinical decision-making tools.

The firm aims to recruit at least 1,000, and up to 5,000, individuals at an elevated risk for pancreatic cancer, comparing its test to standard-of-care surveillance.

News items for the week of Sept. 4, 2023

For the first half of 2023, Centogene reported a 15 percent year-over-year increase in revenues, driven by both its pharma and diagnostics business segments.

A roundup of local coverage determinations from Medicare administrative contractors.

By sequencing samples from an African burial site, researchers got a glimpse at the origins and relationships of individuals liberated from slave ships bound for the Americas.

The collaboration on sequencing library preparation is part of PacBio Compatible, a program launched earlier this year to validate ancillary products.

Natera is offering 4,550,000 common shares at $55 per share in the offering, which is expected to close Sept. 11, with additional shares available to the underwriters.

The test can determine which stroke patients may respond to clopidogrel treatment in about one hour. 

Investigators at the Salk Institute for Biological Studies identified DNA regulatory regions that lead to human pancreatic cancer cell line growth.

Finland-based Euformatics will provide evidence-based quality metrics for different NGS platforms as Cerba considers new sequencing instruments.

Overall revenues fell 30 percent year over year due to a decline in COVID testing as revenues from life science research tools increased 22 percent.

Overall revenues fell 30 percent year over year due to a decline in COVID testing as revenues from life science research tools increased 22 percent.